Our analysis highlighted two hypomethylated CpGs at the promoter region of STX6 (cg05301102 and cg02925840) in multiple genetic forms of FTLD (all subtypes of FTLD2m, including MAPT, GRN and C9orf72 mutation carriers) and in sporadic PSP (FTLD3m), with a much larger effect size in the latter. This evidence concerns the gene MAPT and supranuclear palsy, progressive, 1.